Is Myriad Genetics, Inc. overvalued or undervalued?

As of 4 November 2019, the valuation grade for Myriad Genetics, Inc. moved from expensive to risky, indicating a shift in perception regarding its financial health. Given the current metrics, the company appears to be overvalued, particularly with a Price to Book Value of 0.67 and an EV to Sales ratio of 0.54, which suggest that the market is not pricing in sufficient value relative to its assets and sales. Additionally, the negative EV to EBITDA of -15.22 further underscores the challenges the company faces in generating earnings.
In comparison to its peers, Myriad Genetics, Inc. has a significantly lower EV to EBITDA ratio than Owens & Minor, Inc. at 4.7461 and Pacific Biosciences of California, Inc. at -4.2891, indicating that it is struggling more than its competitors in terms of operational efficiency. Furthermore, the company's stock has underperformed relative to the S&P 500, with a year-to-date return of -43.98% compared to the index's 12.22%, reinforcing the notion that it is currently overvalued.